利拉鲁肽3.0mg每日一次对比安慰剂在代谢手术后体重下降不佳患者中的安全性与有效性:BARI-OPTIMISE随机临床试验
BARI-OPTIMISE随机安慰剂对照试验纳入70例代谢手术后体重下降≤20%且GLP-1反应欠佳的成人患者,比较利拉鲁肽3.0mg每日一次与安慰剂联合生活方式干预24周的效果。主要终点分析显示,利拉鲁肽组体重变化百分比为-8.82%,安慰剂组为-0.54%,组间差异为-8.03%(95%CI -10.39至-5.66;P<.001)。不良反应以胃肠道事件为主,利拉鲁肽组发生28起(80%),安慰剂组20起(57%),无严重不良事件或治疗相关死亡。
要点
- 代谢手术后体重下降不佳且GLP-1反应欠佳者,利拉鲁肽3.0mg每日一次可显著降低体重百分比。
- 24周时利拉鲁肽组体重变化-8.82%,安慰剂组-0.54%,组间差异-8.03%(95%CI -10.39至-5.66;P<.001)。
- 不良反应以胃肠道事件为主,利拉鲁肽组发生率80%,安慰剂组57%,无严重不良事件。
核心结论
- 在代谢手术后体重下降不佳且GLP-1反应欠佳的患者中,辅助使用利拉鲁肽3.0mg每日一次可有效减轻体重。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在英国伦敦2家医院招募至少代谢手术后1年、体重下降≤20%且营养刺激GLP-1反应欠佳的成人患者。
- 研究周期为24周治疗加4周随访,所有参与者和临床研究人员对治疗分配设盲,57例完成随访。
主要发现
- 从基线至第24周,利拉鲁肽3.0mg组(n=31)平均体重变化百分比为-8.82%(SD 4.94),安慰剂组(n=26)为-0.54%(SD 3.32)。
- 利拉鲁肽3.0mg组对比安慰剂的平均体重变化百分比差异为-8.03%(95%CI -10.39至-5.66;P<.001)。
- 不良事件以胃肠道事件为主,利拉鲁肽3.0mg组发生28起(80%),安慰剂组发生20起(57%),无严重不良事件和治疗相关死亡。
临床怎么用
- 对于代谢手术后体重下降不佳且GLP-1反应欠佳的患者,可考虑辅助使用利拉鲁肽3.0mg每日一次进行体重管理。
- 使用利拉鲁肽3.0mg时需监测胃肠道不良反应,试验中该类事件发生率80%。
局限性
- 受COVID-19限制,利拉鲁肽组3例和安慰剂组7例无法参加最终现场评估。
- 利拉鲁肽组2例和安慰剂组1例失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metabolic surgery leads to weight loss and improved health, but these outcomes are highly variable. Poor weight loss is associated with lower circulating levels of glucagon-like peptide-1 (GLP-1). OBJECTIVE: To assess the efficacy and safety of the GLP-1 receptor agonist, liraglutide, 3.0 mg, on percentage body weight reduction in patients with poor weight loss and suboptimal GLP-1 response after metabolic surgery. DESIGN, SETTING, AND PARTICIPANTS: The Evaluation of Liraglutide 3.0 mg in Patients With Poor Weight Loss and a Suboptimal Glucagon-Like Peptide-1 Response (BARI-OPTIMISE) randomized placebo-controlled trial recruited adult patients at least 1 year after metabolic surgery who had experienced 20% or less body weight loss from the day of surgery and a suboptimal nutrient-stimulated GLP-1 response from 2 hospitals in London, United Kingdom, between October 2018 and November 2019. Key exclusion criteria were type 1 diabetes; severe concomitant psychiatric, gastrointestinal, cardiac, kidney or metabolic disease; and use of insulin, GLP-1 receptor analogues, and medication that can affect weight. The study period was 24 weeks followed by a 4-week follow-up period. Last participant follow-up was completed in June 2020. All participants and clinical study personnel were blinded to treatment allocation. Of 154 assessed for eligibility, 70 met trial criteria and were included in the study, and 57 completed follow-up. INTERVENTIONS: Liraglutide, 3.0 mg, once daily or placebo as an adjunct to lifestyle intervention with a 500-kcal daily energy deficit for 24 weeks, on a 1:1 allocation by computer-generated randomization sequence, stratified by surgery type (Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [SG]) and type 2 diabetes status. MAIN OUTCOME AND MEASURES: The primary outcome was change in percentage body weight from baseline to the end of the 24-week study period based on an intention-to-treat analysis. Participant safety was assessed through monitoring of biochemical parameters, including kidney and liver function, physical examination, and assessment for adverse events. RESULTS: A total of 70 participants (mean [SD] age, 47.6 [10.7] years; 52 [74%] female) with a poor weight loss response following RYGB or SG were randomized to receive 3.0-mg liraglutide (n = 35) or placebo (n = 35). All participants received at least 1 dose of the trial drug. Eight participants discontinued treatment (4 per group), and 2 in the 3.0-mg liraglutide group and 1 in the placebo group were lost to follow-up. Due to COVID-19 restrictions, 3 participants in the 3.0-mg liraglutide group and 7 in the placebo group were unable to attend their final in-person assessment. Estimated change in mean (SD) percentage body weight from baseline to week 24 was -8.82 (4.94) with liraglutide, 3.0 mg (n = 31), vs -0.54 (3.32) with placebo (n = 26). The mean difference in percentage body weight change for liraglutide, 3.0 mg, vs placebo was -8.03 (95% CI, -10.39 to -5.66; P < .001). Adverse events, predominantly gastrointestinal, were more frequent with liraglutide, 3.0 mg (28 events [80%]), than placebo (20 events [57%]). There were no serious adverse events and no treatment-related deaths. CONCLUSION AND RELEVANCE: These findings support the use of adjuvant liraglutide, 3.0 mg, for weight management in patients with poor weight loss and suboptimal GLP-1 response after metabolic surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03341429.
引用
- Mok J, Adeleke MO, Brown A, et al. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial. JAMA Surg. 2023. PMID: 37494014. doi:10.1001/jamasurg.2023.2930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。